44 results on '"Pivot, Xavier"'
Search Results
2. Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting
3. Exacerbated central fatigue and reduced exercise capacity in early-stage breast cancer patients treated with chemotherapy
4. Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients
5. Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry
6. Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice
7. Incidental axillary dose delivery to axillary lymph node levels I–III by different techniques of whole-breast irradiation: a systematic literature review
8. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients
9. Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
10. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis
11. Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
12. Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
13. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project
14. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries
15. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
16. Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
17. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
18. Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
19. Can we establish a hierarchy among trastuzumab biosimilar candidates?
20. Critical appraisal of health-state utility values used in breast cancer-related cost–utility analyses
21. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors
22. Awareness and Misconceptions of Breast Cancer Risk Factors Among Laypersons and Physicians
23. Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey
24. Cost–utility analyses of drug therapies in breast cancer: a systematic review
25. Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
26. Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences
27. Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
28. Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?
29. Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06
30. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
31. New Microtubule Inhibitors in Breast Cancer
32. Specific anticancer treatments in the last 3 months of life: a French experience
33. Cabazitaxel: A Novel Microtubule Inhibitor
34. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
35. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
36. Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration: Development of a Limited Sampling Strategy for Toxicity Risk Assessment
37. Cancer screening in France: subjects’ and physicians’ attitudes
38. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer
39. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer
40. Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer
41. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer
42. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients
43. Anthracycline-resistant breast cancer
44. Bevacizumab in First-Line Treatment of Metastatic Breast Cancer: A Viewpoint by Xavier Pivot
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.